ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

被引：60

作者：

Fritzsche F.R. ^{[1
,3
]}

Wassermann K. ^{[1
]}

Jung M. ^{[2
]}

Tölle A. ^{[2
]}

Kristiansen I. ^{[1
]}

Lein M. ^{[2
]}

Johannsen M. ^{[2
]}

Dietel M. ^{[1
]}

Jung K. ^{[2
]}

Kristiansen G. ^{[3
]}

机构：

[1] Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin

[2] Institute of Urology, Charité - Universitätsmedizin Berlin, Berlin

[3] Institute of Surgical Pathology, UniversitätsSpital Zürich, Zurich

来源：

BMC Cancer | / 8卷 / 1期

关键词：

Renal Cell Carcinoma; Renal Cell Cancer; Papillary Renal Cell Carcinoma; Positive Nodal Status; ADAM9 Expression;

D O I：

10.1186/1471-2407-8-179

中图分类号：

学科分类号：

摘要：

Background: A Disintegrin And Metalloprotease (ADAM) 9 has been implicated in tumour progression of various solid tumours, however, little is known about its role in renal cell carcinoma. We evaluated the expression of ADAM9 on protein and transcript level in a clinico-pathologically characterized renal cell cancer cohort. Methods: 108 renal cancer cases were immunostained for ADAM9 on a tissue-micro-array. For 30 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analyzed via quantitative RT-PCR. SPSS 14.0 was used to apply crosstables (Fisher's exact test and χ2-test), correlations and univariate as well as multivariate survival analyses. Results: ADAM9 was significantly up-regulated in renal cancer in comparison to the adjacent normal tissue on mRNA level. On protein level, ADAM9 was significantly associated with higher tumour grade, positive nodal status and distant metastasis. Furthermore, ADAM9 protein expression was significantly associated with shortened patient survival in the univariate analysis. Conclusion: ADAM9 is strongly expressed in a large proportion of renal cell cancers, concordant with findings in other tumour entities. Additionally, ADAM9 expression is significantly associated with markers of unfavourable prognosis. Whether the demonstrated prognostic value of ADAM9 is independent from other tumour parameters will have to be verified in larger study cohorts. © 2008 Fritzsche et al; licensee BioMed Central Ltd.

引用

共 52 条

[1]

Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J., Cancer statistics, 2007, CA: A Cancer Journal for Clinicians, 57, 1, pp. 43-66, (2007)

[2]

McLaughlin J.K., Lipworth L., Epidemiologic aspects of renal cell cancer, Seminars in Oncology, 27, 2, pp. 115-123, (2000)

[3]

Dhote R., Pellicer-Coeuret M., Thiounn N., Debre B., Vidal-Trecan G., Risk factors for adult renal cell carcinoma: A systematic review and implications for prevention, BJU International, 86, 1, pp. 20-27, (2000)

[4]

Dall'Oglio M.F., Arap M.A., Antunes A.A., Cury J., Leite K.R., Srougi M., Impact of clinicopathological parameters in patients treated for renal cell carcinoma, The Journal of Urology, 177, 5, pp. 1687-1691, (2007)

[5]

Breda A., Konijeti R., Lam J.S., Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection, Expert Review of Anticancer Therapy, 7, 6, pp. 847-862, (2007)

[6]

Martignoni G., Brunelli M., Gobbo S., Remo A., Ficarra V., Cossu-Rocca P., Pea M., Chilosi M., Menestrina F., Cheng L., Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Analytical and quantitative cytology and histology, Anal Quant Cytol Histol, 29, 1, pp. 41-49, (2007)

[7]

Rathmell W.K., Martz C.A., Rini B.I., Renal cell carcinoma, Current Opinion in Oncology, 19, 3, pp. 234-240, (2007)

[8]

Young A.N., Master V.A., Amin M.B., Current trends in the molecular classification of renal neoplasms, The Scientific World Journal, 6, pp. 2505-2518, (2006)

[9]

Hammond M.E., Fitzgibbons P.L., Compton C.C., Grignon D.J., Page D.L., Fielding L.P., Bostwick D., Pajak T.F., College of American Pathologists Conference XXXV: Solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants, Archives of Pathology & Laboratory Medicine, 124, 7, pp. 958-965, (2000)

[10]

Yamamoto S., Higuchi Y., Yoshiyama K., Shimizu E., Kataoka M., Hijiya N., Matsuura K., ADAM family proteins in the immune system, Immunology Today, 20, 6, pp. 278-284, (1999)

← 1 2 3 4 5 6 →